Pfizer, Astellas end Caduet agreement in Japan; Novartis' Ultibro tops Advair in COPD study;

> Pfizer Japan and Astellas Pharma have agreed to terminate the Japanese distribution and copromotion agreement for Caduet combo tablets at the end of next March. Report

> New data shows that Novartis' ($NVS) once-daily Ultibro Breezhaler was superior in reducing COPD flare-ups compared with GlaxoSmithKline's ($GSK) Seretide, known as Advair in the U.S. Release

> ThromboGenics' Jetrea has won approval in South Korea. Release

> Mylan ($MYL) will acquire the U.S. rights to DVT drug Arixtra from Aspen. Release

> An FDA advisory committee has recommended against approval of Actavis' ($ACT) Nebivolol/Valsartan fixed-dose combination NDA for the treatment of hypertension. Release

> Omnicom's Adelphi Worldwide has purchased healthcare brand and research agency The Planning Shop international. Story

> Johnson & Johnson ($JNJ) Vision Care is offering a new range of promotional materials designed to help opticians attract, convert and retain contact lens patients. More

And Finally... AmerisourceBergen's ($ABC) new ad campaign uses a mirror concept to illustrate how the company creates a unified brand. More

Suggested Articles

Rather than accept a filing based on phase 1/2 data, the FDA wants Novartis to run a phase 3 for a market-expanding version of gene therapy Zolgensma.

After sifting through the data, one analyst figures the latest Opdivo-Keytruda showdown in kidney cancer might come down to commercial execution.

Call it a fall sports bounce. TV ad spending bumped up in August with the partial return of professional sports, and that included pharma buyers.